Association between the polymorphisms of urokinase plasminogen activation system and cancer risk: a meta-analysis
Zhen Xu1, Li-Li Meng2, Jizong Lin3
1Department of Infectious Diseases, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.
Purpose:
The present study aimed to investigate the potential association between the urokinase plasminogen activation (uPA) system polymorphisms (rs4065, rs2227564, and rs344781) and cancer risk.
Methods:
An extensive search was performed to identify published case-control studies on the association between the uPA system polymorphisms and cancer risk. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate the relationship between the uPA system polymorphisms and cancer risk.
Results:
A total of 20 studies comprising 7,037 cancer cases and 10,094 controls were identified and included in the present meta-analysis. Overall, significantly increased cancer risk was associated with the uPA polymorphism rs4065 (T vs C: OR 1.50, 95% CI: 1.19-1.89; TT vs CC: OR 4.63, 95% CI: 3.10-6.91; dominant model: OR 1.93, 95% CI: 1.60-2.33; recessive model: OR 3.02, 95% CI: 1.26-7.25) and the uPA receptor polymorphism rs344781 (T vs C: OR 1.13, 95% CI: 1.04-1.23; TC vs CC: OR 1.26, 95% CI: 1.06-1.49; TT vs CC: OR 1.35, 95% CI: 1.13-1.63; dominant model: OR 1.29, 95% CI: 1.10-1.52). No significant association was found between the uPA polymorphism rs2227564 and cancer risk. Subgroup analysis suggests that the T allele of the rs4065 (T allele vs C allele: OR 1.50, 95% CI: 1.19-1.89) and rs344781 polymorphisms (T allele vs C allele: OR 1.13, 95% CI: 1.04-1.23) was associated with increased cancer risk in Asians.
Conclusion:
Our results suggest that the uPA polymorphism rs4065 and the uPA receptor polymorphism rs344781 are associated with increased cancer risk.
Related Concept Videos
Cancer Prevention
Some...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase


